BEAT

Rating neutralAI Memo

HeartBeam

As of 2026-09-11/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-11 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

ALIGN-ACS results at TCT 2026 • 2026-10-31

Base target: $1 / p=45% prob

Biggest risk

HeartBeam remains an early-commercial, loss-making micro-cap facing uncertain FDA requirements, an unstarted pivotal study, limited demonstrated revenue and substantial financing risk. Failure to show strong clinical differentiation or repeatable adoption could lead to additional dilution and significant downside.

Invalidation

Break below $0 or thesis failure.

What would change my mind?

Successful TCT data, constructive FDA feedback and conversion of pilot agreements into recurring orders could materially improve validation for HeartBeam's synthesized 12-lead ECG platform. Cost reductions and reported runway into 2027 provide some time to reach these milestones, although the runway claim comes from stored third-party earnings coverage rather than a confirmed company release.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-09-11

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

ATM financing and dilution risk
Evidence of commercial order conversion
Successful TCT data, constructive FDA feedback and conversion of pilot agreements into recurring orders could materially improve validation for HeartBeam's synthesized 12-lead ECG platform.

BearKey bullets

Commercial traction remains early; initial shipments, pilot agreements and positive feedback do not establish recurring revenue or scalable adoption.
Leadership-transition costs and execution demands could distract from clinical, regulatory and commercial milestones.
Peer comparability is weak: large device companies are far more diversified, while similar-sized candidates generally have different products and clinical pathways.

WatchKey bullets

ALIGN-ACS results at TCT 2026

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $1 (p=45%)

Target spread vs base: +100% / -60%

Scenario probabilities

Bull Target: $1 (p=25%)Base Target: $1 (p=45%)Bear Target: $0 (p=30%)

Commentary

Recent coverage is constructive around FDA engagement, clinical enrollment, early shipments and lower cash burn, but it is sparse and largely derived from third-party earnings summaries. Reliable post-print analyst revisions, social sentiment, options skew, short interest and employee-review evidence are unavailable. Treat the positive directional prior as monitoring context rather than confirmation of commercial traction.

As of 2026-09-11 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

ATM financing and dilution risk
Evidence of commercial order conversion

Scenarios

Bull Target (Scenario probability)

$1 / p=25% prob

Base Target (Scenario probability)

$1 / p=45% prob

Bear Target (Scenario probability)

$0 / p=30% prob

Analysis 2026-09-11 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.10

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-31
ALIGN-ACS results at TCT 2026
HeartBeam expects to present full ALIGN-ACS pilot results at TCT 2026 after completing enrollment of 134 patients; the data are intended to inform a U.S. pivotal study and potential indication expansion. Clinical utility and regulatory implications remain unproven [#IR-2026-08-13].
Prob 55.00% • Move 40.00% • Priced-in 30.00%
EVENT2026-12-31
FDA feedback on heart-attack detection pathway
Stored Q2 earnings coverage reports that HeartBeam submitted an FDA pre-submission proposing a 510(k) pathway and anticipated feedback within 75 days, potentially clarifying pivotal-trial design and whether a study can begin by year-end 2026 [#PR-EARNINGS-2026-08-14].
Prob 45.00% • Move 30.00% • Priced-in 20.00%

Short-term Catalysts

Next few weeks

ATM financing and dilution risk
2026-12-31
An August 2026 SEC filing describes potential at-the-market sales through ordinary broker transactions. With operations still loss-making, issuance could pressure the share price and dilute existing holders [#8-K-2026-08-14].
Prob 65% • Move -35% • Priced-in 45%

Long-term Catalysts

Months to a year

Evidence of commercial order conversion
2026-12-31
Stored Q2 earnings coverage reports initial shipments and agreements across four U.S. markets, but also characterizes commercialization as early and without significant revenue. Meaningful patient onboarding and repeat orders would be required to validate adoption [#PR-EARNINGS-2026-08-14].
Prob 40% • Move 35% • Priced-in 30%

Risks

Commercial traction remains early; initial shipments, pilot agreements and positive feedback do not establish recurring revenue or scalable adoption.
Leadership-transition costs and execution demands could distract from clinical, regulatory and commercial milestones.
Peer comparability is weak: large device companies are far more diversified, while similar-sized candidates generally have different products and clinical pathways.
Stored Q2 coverage reports $8.8 million of cash at June 30, 2026 and a $5.0 million quarterly net loss, indicating continued dependence on cost control and external capital.
The August 2026 ATM filing creates meaningful dilution and share-price-overhang risk [#8-K-2026-08-14].
The pivotal study for heart-attack detection has not begun, and FDA feedback could require a larger, longer or more expensive program than anticipated.

Peers

Symbol	Summary
ABT	Large, diversified cardiovascular-device benchmark; its established distribution, reimbursement infrastructure and financial scale make it unsuitable as a direct valuation comparable.
BSX	Relevant cardiac-device commercialization and regulatory benchmark, but its scale and mature portfolio sharply limit direct comparability with pre-scale HeartBeam.
CTSO	Closer small-cap financing-risk reference, although its therapeutic focus differs materially; useful mainly for comparing capital durability and commercialization execution.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-11

Loading AI feed…

Symbol

Summary

ABT

Large, diversified cardiovascular-device benchmark; its established distribution, reimbursement infrastructure and financial scale make it unsuitable as a direct valuation comparable.

BSX

Relevant cardiac-device commercialization and regulatory benchmark, but its scale and mature portfolio sharply limit direct comparability with pre-scale HeartBeam.

CTSO

Closer small-cap financing-risk reference, although its therapeutic focus differs materially; useful mainly for comparing capital durability and commercialization execution.